Receptor Information
General Information of This Receptor
| Receptor ID |
REC00034
|
|||||
|---|---|---|---|---|---|---|
| Receptor Name |
Kappa-type opioid receptor (OPRK1)
|
|||||
| Gene Name |
OPRK1
|
|||||
| Gene ID | ||||||
| Synonym |
OPRK
|
|||||
| Sequence |
MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV
IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV RNTVQDPAYLRDIDGMNKPV
Click to Show/Hide
|
|||||
| 3D Structure | ||||||
| Family |
the G-protein coupled receptor 1 family
|
|||||
| Function |
G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
Click to Show/Hide
|
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Each Peptide-drug Conjuate AND It's Component Related to This Receptor
Full List of The PDC Related to This Receptor
DAyaVCTf
| PDC Info | PDC Name | Drug | Target | Linker |
|---|---|---|---|---|
|
De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) conjugates 3
|
β-Naloxamine
|
Kappa-type opioid receptor (OPRK1)
|
Amide bond
|
sdhAACSf
| PDC Info | PDC Name | Drug | Target | Linker |
|---|---|---|---|---|
|
De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) conjugates 4
|
β-Naloxamine
|
Kappa-type opioid receptor (OPRK1)
|
Amide bond
|
tNeslCSf
| PDC Info | PDC Name | Drug | Target | Linker |
|---|---|---|---|---|
|
De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) conjugates 2
|
β-Naloxamine
|
Kappa-type opioid receptor (OPRK1)
|
Amide bond
|
YAyITCTF
| PDC Info | PDC Name | Drug | Target | Linker |
|---|---|---|---|---|
|
De Novo Cyclic Peptide (DNCP)-β-naloxamine (NalA) conjugates 1
|
β-Naloxamine
|
Kappa-type opioid receptor (OPRK1)
|
Amide bond
|
